Sanofi US News

- All six trials met primary efficacy endpoint -

- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments -

Generics Division of Sanofi, Winthrop US, to Market the Drug

- Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine –

- Toujeo dossier already accepted by EMA -

- Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® -

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions --

During the 1-year program, patients showed statistically significant reductions in blood glucose levels, increased belief in their ability to self-manage their diabetes and improved perceptions of support, while the community showed statistically significant increases in diabetes awareness

For Millions Of Sufferers, Heartburn Can Be Spelled Many Different Ways But Relief Can Always Be Spelled R-O-L-A-I-D-S

$100,000 prize and access to additional expertise awarded to support "big data" genetic analysis to provide new clues to the higher incidence of ALS in veterans

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT

Pathway to Stop Diabetes will provide funding for innovative diabetes researchers

- Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment -

Developing approaches for involving patients in drug development

- Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal -

- EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus® -

- Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints -

- Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin -

- Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children -

- Connect & Coach™ Awarded $100,000 to Further Develop its Novel Solution to Help Improve Health Outcomes for People Living with Diabetes -

Growth platforms(2) sales increased 8.6%(3)

Pathway to Stop Diabetes to provide funding for innovative diabetes researchers

- Sanofi US to Donate Up to $100,000 to Patient Organizations -

- NBA All-Stars Andre Iguodala and Danny Granger and Seven-Time WNBA All-Star Tamika Catchings to Help Raise Awareness about Diabetes -

-- Product acquisition further strengthens Consumer Healthcare Division of Sanofi US --

Pathway to Stop Diabetes to Provide Funding for Innovative Diabetes Researchers

- New Data Presented at American Society of Hematology Annual Meeting Show Activity Against Disease and Symptom Alleviation -

Response Includes Contribution to Three New Jersey Area Organizations

Growth Platforms(2) reached over 70% of sales

Establishment of joint project teams will leverage strengths of academic and industry cross-organizational expertise in all stages of translational research

- Goal is to select novel clinical development candidates to help stop the global pandemic -

-- Breakthrough device design talks patients and caregivers through the injection process --

Novel Ideas Sought on How to Better Engage Patients in Their Health

Research collaboration to explore novel target shown in pre-clinical studies to play significant role in type 1 diabetes

- Research collaboration with affiliate of Harvard Medical School aims to develop novel therapeutic approaches -

- Fox Foundation to sponsor a clinical trial to study Sanofi compound -

- Sanofi to commercialize LeGoo® a highly innovative FDA approved and CE marked gel that provides temporary blood vessel occlusion during surgery -

Challenge Now Accepting Submissions From Health Innovators and Entrepreneurs

Net Sales and Business EPS(1) up 9.2%(2) in Q4

- NBA Star Carlos Boozer, WNBA All-Star Tamika Catchings, NBA Legend Bob Lanier and New Jersey Nets Head Coach Avery Johnson to Serve as Campaign Ambassadors -

JOINTLY RELEASED BY SANOFI AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

- Performance driven by growth platforms, Genzyme acquisition and cost savings -

Sanofi demonstrates commitment to wellness and prevention starts with its own employees

Positive impact from Genzyme on business EPS(1)

- Data Presented at American Diabetes Association's 71st Annual Scientific Sessions -

- Once-Daily Lyxumia® Demonstrates Non-Inferior Reduction of Blood Glucose and Less Hypoglycemia versus Exenatide Twice Daily in Type 2 Diabetes Patients -

Diabetes Co-Stars: Cook-Off Invites People to Share Diabetes-Friendly Recipes

U.S. locations launch a “Walking Club” and promote a myriad of programs offered to employees to improve overall health and wellness

- WNBA, NBA Development League and NBA All-Star Dwight Howard, WNBA All-Star Alana Beard and NBA Legends Walt Frazier and Chris Dudley will also Raise Awareness about Diabetes -

Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its footprint in biotechnology

- First industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR) -

- Collaboration promotes clinical and translational research to address unmet needs of cancer patients in India -

- Focused on translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation -

- Funding supports programs to advance personalized medicine -

- Alliance formed to advance cutting-edge research and foster collaboration between academia and industry -

- Sanofi-aventis Supports Consortium's Activities to Fund Promising Early-Stage Life Sciences Companies -

Chattem Becomes the U.S. Consumer Healthcare Platform for sanofi-aventis

Ben Vereen to Extend National Diabetes Awareness Campaign in Six Additional Cities

Interdisciplinary team of experts joins forces to discuss the latest tools to combat this preventable but deadly disease

Development and Commercialization for Cetrorelix Pamoate in Benign Prostatic Hyperplasia